CHARLOTTESVILLE, Va., Nov. 14 /PRNewswire/ -- Diffusion Pharmaceuticals
LLC, a drug discovery and development company pioneering a revolutionary
approach to treat life-threatening diseases, today announced that it has
appointed Matthew W. Hantzmon to the new position of Vice President,
Business Development. Mr. Hantzmon, a senior executive with a successful
record in medical technology and renewable energy start-up companies, is
now responsible for Diffusion Pharmaceuticals' strategic partnerships. This
follows the company's recent announcement that it has completed a $1.5
million private funding round and completed all animal toxicology studies
required by the U.S. Food and Drug Administration (FDA) to file an
investigational new drug (IND) application for its lead compound trans
sodium crocetinate (TSC).
(Photo: http://www.newscom.com/cgi-bin/prnh/20061114/DCTU061 )
"Mr. Hantzmon has a tremendous combination of corporate management and
business development experience that will enable us to expand our business
development activities," said David G. Kalergis, Diffusion's Chief
Executive Officer. "As an early investor and co-author of Diffusion's first
business plan, he is very familiar with our platform technology and is
committed to the rapid and efficient commercialization of our pipeline of
novel small-molecule therapeutics."
Mr. Hantzmon comes to Diffusion from Greenlight Energy, Inc., an
independent power producer focused on wind energy projects, where he worked
from 2001 until 2006 when the company was sold to British Petroleum (BP)
for $98 million. As Managing Director at Greenlight, Mr. Hantzmon was
instrumental in the negotiations that led to the sale.
Before Greenlight Energy, he was a co-founder and President of GeNeuron
Therapeutics, Inc., a biotechnology company, which developed biologically-
enhanced medical devices for the treatment of neurovascular diseases.
Previously, Mr. Hantzmon was Director of International Market
Development for Varian Medical Systems. In this role, he was responsible
for marketing, sales, and business development for all geographies outside
North America. Prior to its acquisition by Varian in 1999, he had been Vice
President and COO at Multimedia Medical Systems, Inc., a biotechnology
company focusing on radiation treatment planning systems. Other roles as a
founding member of MMS included Secretary, Treasurer and Chief Financial
Officer. In his early career, he was a Senior Financial Analyst for IBM and
a Management Consultant for Price Waterhouse, LLC.
He is a founder and board member of Columbia Power Technologies, a
development stage company focused on conversion of wave energy into
electricity. Mr. Hantzmon holds a B.A. degree from the University of
Virginia and an MBA from the Kellogg Graduate School of Management at
Northwestern University. He is also a Certified Management Accountant.
About Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals LLC is a drug discovery and development
company that owns a platform technology of patented small molecule
therapeutics that enhance the diffusion of oxygen to hypoxic
(oxygen-starved) tissues. By applying a revolutionary approach to increase
oxygen diffusion into tissue cells, Diffusion's lead molecule trans sodium
crocetinate (TSC) and other proprietary pipeline molecules could be used to
treat life-threatening conditions, such as trauma, stroke, cardiovascular,
respiratory, and other conditions characterized by oxygen deprivation at
the cellular level. The company's pipeline drugs, known as trans bipolar
carotenoid or TBC molecules, are currently in the preclinical stage.
Clinical trials are planned to support the use of TSC in ischemic
indications. Diffusion Pharmaceuticals, which is privately held, is located
in Charlottesville, Virginia. For more information, visit
http://www.diffusionpharma.com.
SOURCE Diffusion Pharmaceuticals LLC
 back to top
Related links:
http://www.diffusionpharma.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20061114/DCTU061
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Tracey Linkous, Director of Communications of
Diffusion Pharmaceuticals LLC, +1-434-220-0718,
tlinkous@diffusionpharma.com
|
